Explore every episode of the podcast Eagle's Eye View: Your Weekly CV Update From ACC.org
| Title | Pub. Date | Duration | |
|---|---|---|---|
| Risk Stratification in Nonischemic Dilated Cardiomyopathy, 2024 Guideline for Perioperative CV Management for Noncardiac Surgery, Lipoprotein(a) and Cardiovascular Disease | 25 Sep 2024 | 00:08:53 | |
In this week’s View, Dr. Eagle looks at risk stratification in nonischemic dilated cardiomyopathy using CMR imaging. He then discusses the recent update of the Guideline for Perioperative CV Management for Noncardiac Surgery. Finally, Dr. Eagle talks about a review article on lipoprotein(a) and CVD. | |||
| Long-Term Outcomes in Pericarditis, Polygenic Risk Score and Predicting CVD, Aortic Disease in Children with FBN1-Related Marfan Syndrome | 18 Sep 2024 | 00:10:36 | |
In this week’s View, Dr. Eagle looks at predicting long-term outcomes in patients with recurrent pericarditis. He then explores how the polygenic risk score may add to the clinical risk estimate for predicting cardiovascular disease in populations. Finally, Dr. Eagle discusses the management of aortic disease in children with FBN1-related Marfan syndrome. | |||
| Diuretics and HF, Implantable Cardioverter-Defibrillators and the Tricuspid Valve and Right Ventricle, Neurohormonal Blockade and HF | 24 Jul 2024 | 00:08:47 | |
In this week’s View, Dr. Eagle looks at a study comparing three diuretic regimens in ambulatory congested heart failure (HF) patients (DEA-HF). He then explores a randomized trial that investigates the effects of implantable cardioverter-defibrillator (ICD) leads on the tricuspid valve and right ventricle. Finally, Dr. Eagle discusses the effects of rapid up-titration of neurohormonal blockade in patients with acute decompensated HF. | |||
| Racial Differences in Diabetic Cardiomyopathy, Genetics of HCM, Semaglutide vs. Tirzepatide for Weight Loss | 17 Jul 2024 | 00:08:59 | |
In this week’s View, Dr. Eagle looks at the ARISE-HF trial that examined racial differences in diabetic cardiomyopathy. He then explores established and emerging implications of treatment of genetic hypertrophic cardiomyopathy (HCM). Finally, Dr. Eagle discusses the use of GLP-1 agonists, including semaglutide vs. tirzepatide for weight loss in adults with overweight or obesity.
| |||
| Iron Repletion and Heart Failure, Ventricular Septal Defect and Acute Myocardial Infarction, Hemodynamic Assessment for HF | 10 Jul 2024 | 00:09:09 | |
In this week’s View, Dr. Eagle discusses a state-of-the-art review on iron repletion for patients with heart failure and iron deficiency. He then explores the diagnosis and management of ventricular septal defect complicating acute myocardial infarction. Finally, Dr. Eagle discusses practical guidance for hemodynamic assessment by right heart catheterization in management of heart failure. | |||
| Early Rhythm Control, Low-Dose Aspirin and Prevention, Autoimmune Diseases and Atherosclerosis | 02 Jul 2024 | 00:08:37 | |
In this week’s View, Dr. Eagle looks at the clinical impact of early rhythm control and healthy lifestyles in patients with atrial fibrillation, then explores the use of low-dose aspirin in the prevention of atherosclerotic cardiovascular disease. Finally, Dr. Eagle discusses the association of autoimmune diseases with coronary atherosclerosis and ischemic events. | |||
| In-office and At-Home Blood Pressure Measurement, Artificial Intelligence and Cardiovascular Care, Inflammatory Risk | 26 Jun 2024 | 00:07:09 | |
In this week’s View, Dr. Eagle looks at office measurement vs. ambulatory blood pressure monitoring and its associations with mortality in patients with or without diabetes. Dr. Eagle then reviews two related articles: a report in JACC on Artificial Intelligence and cardiovascular care, and a recent article from The Lancet on inflammatory risk and cardiovascular events in patients without obstructive coronary artery disease in which AI played an important role.
| |||
| Severe Aortic Stenosis, Titration and Acute Heart Failure, Pacemakers After TAVR | 18 Jun 2024 | 00:07:53 | |
In this week’s View, Dr. Eagle looks at secular trends of incidence and outcomes in severe aortic stenosis. He then examines titration of medications after acute heart failure. Finally, Dr. Eagle shares some thoughts on an analysis from the PARTNER2-S3 registry on the predictors and five-year clinical outcomes of pacemakers after TAVR. | |||
| Excess Apolipoprotein-B and Cardiovascular Risk, Treating Pulmonary Arterial Hypertension, SGLT2i and CV Outcomes | 12 Jun 2024 | 00:08:42 | |
In this week’s View, Dr. Eagle looks at excess apolipoprotein-B and cardiovascular risk, then examines a recent meta-analysis on treating pulmonary arterial hypertension. Finally, Dr. Eagle shares some thoughts on a SMART-C collaborative meta-analysis of sodium-glucose cotransporter-2 inhibitors and major adverse cardiovascular outcomes. | |||
| Anticoagulation in Post-Operative AFib, Non-ST-Elevation Acute Coronary Syndromes, Arrhythmia-Induced Cardiomyopathy | 05 Jun 2024 | 00:10:57 | |
In this week’s View, Dr. Eagle looks at anticoagulation for post-operative atrial fibrillation after isolated coronary artery bypass grafting. He then examines a meta-analysis of invasive vs. conservative management of non-ST-elevation acute coronary syndromes with previous coronary artery bypass grafting. Finally, Dr. Eagle shares some thoughts on JACC’s recent State of the Art Review of arrhythmia-induced cardiomyopathy. | |||
| Aortic Valve Calcification and Aortic Stenosis, Microvascular Resistance Reserve After PCI, Microvascular Injury Patterns | 29 May 2024 | 00:07:42 | |
In this week’s View, Dr. Eagle looks at the diagnostic value of aortic valve calcification levels in the assessment of low-gradient aortic stenosis. He then examines the prognostic value of microvascular resistance reserve after percutaneous coronary intervention in patients with myocardial infarction. Finally, Dr. Eagle shares some thoughts on clinical outcomes associated with various microvascular injury patterns identified by cardiac MRI after STEMI. | |||
| Transcatheter-Based Intervention and Tetralogy of Fallot, Small Left Ventricle and Atrial Fibrillation (Afib), Aspirin Free Treatment Post-PCI | 22 May 2024 | 00:09:39 | |
In this week’s View, Dr. Eagle looks at transcatheter-based intervention for tetraology of Fallot. He then examines how a small left ventricle in patients with atrial fibrillation is associated with increased cardiovascular risk. Finally, Dr. Eagle shares some thoughts on an aspirin-free strategy for immediate treatment following complex percutaneous coronary intervention. | |||
| Eight Practice-Changing Trials Featured at ESC Congress 2024 | 12 Sep 2024 | 00:11:02 | |
In this special edition of Eagle’s Eye View, Dr. Eagle summarizes the most important trials that were featured at the ESC Congress 2024, August 30 to September 2—eight trials that could have significant influence on your day-to-day practice. They include: FINEARTS-HF, exploring the benefits of finerenone in patients with HFmrEF or HFpEF; SCOFF, asking if fasting prior to cath lab procedures is necessary; SENIOR-RITA on CV management in frail adults; SHAM-PVI, exploring pulmonary vein isolation vs. sham intervention in patients with asymptomatic AFib; ASSURE DES, examining continuing vs. interruptive aspirin therapy before noncardiac surgery in patients with DES; Stop-or-Not, on the continuation vs. discontinuation of RASIs prior to major noncardiac surgery; ABYSS, exploring the impact of interrupting or continuing beta-blocker treatment in patients with a history of MI; and RESHAPE-HF2, on the impact of M-TEER on patients with FMR and symptomatic HF. | |||
| Guideline for the Management of Lower Extremity Peripheral Artery Disease (PAD), Decongestion Strategies for Heart Failure, Lipoproteins and Triglycerides in Cardiovascular Prevention | 15 May 2024 | 00:10:53 | |
In this week’s View, Dr. Eagle looks at the recently released guidelines for lower extremity peripheral arterial disease (PAD). He then examines a national community-based cohort study on contemporary decongestion strategies in patients hospitalized for heart failure. Finally, Dr. Eagle shares some thoughts on the implications of discordance among ApoB, non–high-density lipoprotein cholesterol and triglycerides for cardiovascular prevention. | |||
| Eagle’s Eye View: The New AHA/ACC Hypertrophic Cardiomyopathy Guideline, Smoking Cessation, Embolic Stroke | 08 May 2024 | 00:10:58 | |
In this week’s View, Dr. Eagle looks at the new AHA/ACC Hypertrophic Cardiomyopathy Guideline, then examines a randomized clinical trial that studied smoking cessation after initial treatment failure with varenicline or nicotine. Finally, Dr. Eagle shares some thoughts on a clinical consensus statement of the ESC Council on Stroke, the European Association of Cardiovascular Imaging, and the European Heart Rhythm Association of the ESC on embolic strokes of an undetermined source. | |||
| Eagle’s Eye View: Pulsed Field Ablation and Pulmonary Vein Isolation, Penetrance of Dilated Cardiomyopathy in Genotype-Positive Relatives, TAVR or SAVR and Severe Aortic Stenosis | 01 May 2024 | 00:08:52 | |
In this week’s View, Dr. Eagle looks at the durability of pulmonary vein isolation using pulsed-field ablation, then examines genetic penetrance of dilated cardiomyopathy in genotype-positive relatives. Finally, Dr. Eagle shares some thoughts on reinterventions after CoreValve/Evolut TAVR or SAVR for treatment of severe aortic stenosis. | |||
| Eagle’s Eye View: Cardiac Sarcoidosis, Ischemic Stroke in Women with Atrial Fibrillation, TAVR and Native Aortic Regurgitation | 24 Apr 2024 | 00:09:38 | |
In this week’s View, Dr. Eagle looks at a scientific statement from the American Heart Association on the diagnosis and management of cardiac sarcoidosis. He then examines the temporal trends and clinical implications of ischemic stroke in women with atrial fibrillation. Finally, Dr. Eagle shares some thoughts on transcatheter aortic valve implantation in patients with high-risk symptomatic native aortic regurgitation (ALIGN-AR). | |||
| Eagle’s Eye View: infective Endocarditis After Invasive Dental Procedures, Serious Bleeding in Patients with Atrial Fibrillation Using Diltiazem with Apixaban or Rivaroxaban, Low-Dose Colchicine for Secondary Prevention in Atherosclerosis | 17 Apr 2024 | 00:09:50 | |
In this week’s View, Dr. Eagle looks at a systematic review and meta-analysis of antibiotic prophylaxis and infective endocarditis incidence following invasive dental procedures. He then examines the issue of serious bleeding in patients with atrial fibrillation using diltiazem with apixaban or rivaroxaban. Finally, Dr. Eagle shares some thoughts on low-dose colchicine for secondary prevention in atherosclerosis.
| |||
| Eagle’s Eye View: Introducing ACC24 | 10 Apr 2024 | 00:03:35 | |
In this special edition of Eagle’s Eye View, Dr. Eagle introduces you to ACC24 featuring valuable insights into practice-changing updates in care. The topics include late-breaking clinical trials and science focusing on new drugs and device therapies. Tune into ACC.org’s coverage of ACC.24 to hear from the top experts as they debate, discuss the results of the trials, share visual abstracts and find out how it all fits into your practice. The transformation of care begins at ACC.24.
| |||
| Eagle’s Eye View: Day 3 -- ACCess Points Daily Wrap Up | ACC 2024 | 08 Apr 2024 | 00:10:29 | |
Drs. Kim Eagle, Dharam Kumbhani, Payal Kohli, and Ajay Kirtane review the late-breaking clinical trials from Day 3, Monday, April 7 at the American College of Cardiology Scientific Sessions 2024 in Atlanta. Trials on Monday include TARGET BP I (0:39), DEDICATE-DZHK6 (3:07), and FULL REVASC (6:31). For trial summaries, news coverage, daily video wrap-ups and more, visit ACC's Meeting Coverage Page. Follow the ACC on Social Media and use the hashtag #ACC24. | |||
| Eagle’s Eye View: Day 2 -- ACCess Points Daily Wrap Up | ACC 2024 | 07 Apr 2024 | 00:11:12 | |
Drs. Kim Eagle, Dharam Kumbhani, Payal Kohli, and Ajay Kirtane review the late-breaking clinical trials from Day 2, Sunday, April 6 at the American College of Cardiology Scientific Sessions 2024 in Atlanta. Trials on Sunday include REDUCE-AMI (0:35), DanGer-Shock (3:28), ULTIMATE-DAPT (6:17) and TACT2 (10:04). For trial summaries, news coverage, daily video wrap-ups and more, visit ACC's Meeting Coverage Page. Follow the ACC on Social Media and use the hashtag #ACC24.
| |||
| Eagle’s Eye View: Day 1 -- ACCess Points Daily Wrap Up | ACC 2024 | 06 Apr 2024 | 00:09:35 | |
Drs. Kim Eagle, Dharam Kumbhani, Payal Kohli, and Ajay Kirtane review the late-breaking clinical trials from Day 1, Saturday, April 5 at the American College of Cardiology Scientific Sessions 2024 in Atlanta. Trials on Saturday include AEGIS II (0:45), VICTORION-INITIATE (2:36), RELIEVE-HF (5:27) and Step-HFpEF Dm (8:42). For trial summaries, news coverage, daily video wrap-ups and more, visit ACC's Meeting Coverage Page. Follow the ACC on Social Media and use the hashtag #ACC24.
| |||
| Eagle’s Eye View: Multivessel Revascularization, Wearable Heart Rate Monitors, Sports-Related Sudden Cardiac Death | 03 Apr 2024 | 00:09:00 | |
In this week’s View, Dr. Eagle looks at the timing of complete multivessel revascularization in patients presenting with non-ST-Elevation Acute Coronary Syndrome, then examines the accuracy of wearable heart rate monitors during exercise in sinus rhythm and atrial fibrillation. Finally, Dr. Eagle shares some thoughts on a multinational observation study on sports-related sudden cardiac death.
| |||
| Mechanical Circulatory Support in Infarct-Related Cardiogenic Shock, Anticoagulation Benefit in Device-Detected AFib, Semaglutide in HFpEF Patients | 11 Sep 2024 | 00:08:25 | |
In this week’s View, Dr. Eagle looks at temporary mechanical circulatory support in infarct-related cardiogenic shock. He then explores the anticoagulation benefit in device-detected atrial fibrillation with or without vascular disease as reported in a combined analysis of the NOAH-AFNET 6 and ARTESiA trials. Finally, Dr. Eagle discusses a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomized trials that documented the effectiveness of semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction. | |||
| Eagle’s Eye View: A Preview of ACC.24 | 01 Apr 2024 | 00:06:23 | |
In this special edition of Eagle’s Eye View, Dr. Eagle highlights the latest science and innovation being presented at ACC.24 in Atlanta, Georgia from April 6-8. He gives us valuable insights into practice-changing updates in care. The topics include late-breaking clinical trials and science focusing on new drugs and device therapies. Tune into ACC.org’s coverage of ACC.24 to hear from the top experts as they debate, discuss the results of the trials, share visual abstracts and find out how it all fits into your practice. The transformation of care begins at ACC.24. | |||
| Eagle’s Eye View: Sacubitril/Valsartan in Decompensated Heart Failure; Discordant Aortic Stenosis and Transcatheter Treatment of Tricuspid Valve Regurgitation | 27 Mar 2024 | 00:11:11 | |
In this week’s View, Dr. Eagle looks at sacubitril/valsartan in patients hospitalized with decompensated heart failure, then examines the prevalence and outcomes of patients with discordant high gradient aortic stenosis. Finally, Dr. Eagle shares some thoughts on current concepts regarding transcatheter treatment of tricuspid valve regurgitation. | |||
| Eagle’s Eye View: Quantitative Coronary Angiography vs Intervascular Ultrasound to Guide PCI, Paclitaxel-Coated Balloon Catheters, PCI vs Coronary Artery Bypass Grafting in Left Main Disease and Diabetes | 20 Mar 2024 | 00:08:17 | |
In this week’s View, Dr. Eagle looks at the difference between quantitative coronary angiography versus intervascular ultrasound to guide PCI. He then discusses paclitaxel-coated balloon catheters vs uncoated balloon angioplasty for treating coronary in-stent restenosis. Finally, Dr. Eagle discusses four studies comparing percutaneous coronary intervention versus coronary artery bypass grafting in patients with left main disease with or without diabetes. | |||
| Eagle’s Eye View: Blood Pressure and PAD, Leadless Pacemakers, Palliative Care and Heart Failure | 13 Mar 2024 | 00:08:42 | |
In this week’s View, Dr. Eagle covers various blood pressure parameters and their predictability for peripheral arterial disease (PAD) and complications, then explores the five-year outcomes of leadless pacemakers. Finally, Dr. Eagle discusses the role of palliative care in the spectrum of treating patients with heart failure. | |||
| Eagle’s Eye View: Lipoprotein(a), Cardiovascular Disease, Interoperative Anemia and Sex Disparity and the Effectiveness of Surveillance Stress Testing | 06 Mar 2024 | 00:08:59 | |
This week, Dr. Eagle dedicates this episode of Eagle’s Eye View to JACC and the upcoming special issue of the Journal edited by Dr. Fuster. Dr. Eagle comments cover JACC articles on lipoprotein(a) and major adverse cardiovascular events in patients with or without baseline atherosclerotic cardiovascular disease, then explores intraoperative anemia and how it mediates sex disparity in operative mortality after coronary artery bypass grafting. Finally, Dr. Eagle talks about the value of surveillance stress testing after percutaneous intervention for patients with multivessel or left main coronary disease. | |||
| Eagle’s Eye View: ASCVD Risk and Diabetes, TRI-SCORE , Severe Tricuspid Regurgitation, COVID Boosters and Myocarditis | 28 Feb 2024 | 00:09:52 | |
In this week’s View, Dr. Eagle covers coronary calcium scores and how they predict ASCVD risk in the presence of left main disease and diabetes. He then explores TRI-SCORE and the benefits of intervention in patients with severe tricuspid regurgitation. Finally, Dr. Eagle talks about booster vaccination with SARS-CoV-2 mRNA vaccines and myocarditis in adolescents and young adults. | |||
| Eagle’s Eye View: Postpartum Cardiovascular Risk, Cardiac Risk and Spinal Cord Injury, Imaging and Percutaneous Coronary Intervention | 21 Feb 2024 | 00:09:18 | |
In this week’s View, Dr. Eagle covers opportunities in the postpartum period to reduce cardiovascular disease risk after adverse pregnancy outcomes. He then explores the apparent increased risk of myocardial infarction, heart failure and atrial fibrillation after spinal cord injury. Finally, Dr. Eagle talks about a systematic review and network meta-analysis of coronary angiography, intravascular ultrasound, and optical coherence tomography in the guidance of percutaneous coronary intervention. | |||
| Eagle’s Eye View: The AHA’s PREVENT Equations, Implantable Hemodynamic Monitors and the NOTION Trial | 14 Feb 2024 | 00:08:30 | |
In this week’s View, Dr. Eagle discusses the development and validation of the American Heart Association’s PREVENT risk assessment tool. He then explores implantable hemodynamic monitors and their role in improving survival in patients with heart failure and reduced ejection fraction. Finally, Dr. Eagle talks about the 10-year outcomes of the NOTION trial regarding transcatheter or surgical aortic valve implantation. | |||
| Eagle’s Eye View: Recovery in Peripartum Cardiomyopathy, Physical Activity and Cognitive Decline, Consumer Mobile Technologies | 07 Feb 2024 | 00:09:04 | |
In this week’s View, Dr. Eagle discusses recovery in peripartum cardiomyopathy. He then explores a systematic review and meta-analysis of the association of physical activity and cognitive decline among older adults. Finally, Dr. Eagle talks about the promises and perils of consumer mobile technologies in cardiovascular care. | |||
| Eagle’s Eye View: NOAC vs. Warfarin For AFib, Sex Disparities in Medical-Guided Therapy Among HFrEF Patients, Polygenic Risk in Families With Spontaneous SCAD | 31 Jan 2024 | 00:09:10 | |
In this week’s View, Dr. Eagle discusses the use of non–Vitamin-K antagonist oral anticoagulants versus warfarin across the spectrum of body mass index and weight. He then explores sex disparities in longitudinal use and intensification of guideline-directed medical therapy among patients with newly diagnosed heart failure with reduced ejection fraction. Finally, Dr. Eagle talks about polygenic risk in families with spontaneous coronary artery dissection. | |||
| SGLT2 Inhibitors vs. GLP-1 RAs in Diabetes, MRI Lesions After TAVR, Perioperative Management and Anticoagulants | 04 Sep 2024 | 00:09:50 | |
In this week’s View, Dr. Eagle looks at the kidney and cardiovascular effectiveness of SGLT2 inhibitors versus GLP-1 receptor agonists in type 2 diabetes. He then explores the prognostic ability of diffusion-weighted brain MRI lesions after TAVR. Finally, Dr. Eagle discusses perioperative management of patients taking direct oral anticoagulants, particularly those being considered for noncardiac surgery. | |||
| Eagle’s Eye View: When DOACS Should Not Be Used as Standard Treatment, Intervention for Complex Coronary Lesions through OCT vs IVUS, Impact of Bempedoic Acid on CV Events | 24 Jan 2024 | 00:09:01 | |
In this week’s View, Dr. Eagle discusses a JACC State of the Art Review noting direct oral anticoagulants (DOACs) should not be standard treatment. He then explores various ways of guiding intervention for complex coronary lesions by optical coherence tomography (OCT) or intravascular ultrasound (IVUS). Finally, Dr. Eagle talks about a prespecified analysis of the CLEAR Outcomes Randomized Trial on the impact of bempedoic acid on total cardiovascular events. | |||
| Eagle’s Eye View: ‘False Positive’ Exercise ECG Tests, Oral Coagulants v. Vitamin K Antagonists, Outcomes Following the Ross Procedure | 17 Jan 2024 | 00:08:38 | |
In this week’s View, Dr. Eagle explores rethinking “false positive” exercise ECG Tests in patients with microvascular dysfunction. He then discusses a recent comparison of direct oral anticoagulants vs Vitamin K antagonists after transcatheter mitral valve replacement. Finally, Dr. Eagle examines a post-hoc analysis of a randomized clinical trial assessing long-term clinical and echocardiographic outcomes following the Ross procedure. | |||
| Eagle’s Eye View: Artificial Intelligence in Cardiology, Arterial Thromboembolism, and the Advanced Cardiovascular Life Support (ACLS) Guidelines | 10 Jan 2024 | 00:09:21 | |
In this week’s View, Dr. Eagle explores using AI Large Language Models for cardiology. He then discusses arterial thromboembolism in patients with atrial fibrillation and a CHA2DS2-VASc score of 1. Finally, Dr. Eagle examines a focused update on the Advanced Cardiovascular Life Support Guidelines. | |||
| Eagle’s Eye View: The Year in Cardiology: 2023 in Review | 22 Dec 2023 | 00:04:16 | |
In this week’s View, Dr. Eagle explores the breakthroughs, trends, and major developments in cardiology over the last twelve months. | |||
| Eagle’s Eye View: What is the Importance of Residual Leaks Following Percutaneous Left Atrial Appendage Occlusion and Outcomes? | 20 Dec 2023 | 00:10:44 | |
In this week’s View, Dr. Eagle explores the disparities in diagnosis, treatment, and outcomes of peripheral artery disease. He then discusses evolving multimodality cardiac imaging in managing transthyretin amyloid cardiomyopathy. Finally, Dr. Eagle examines the importance of residual leaks following percutaneous left atrial appendage occlusion and outcomes. | |||
| Eagle’s Eye View: What is the Safety and Tolerability of Inclisiran in Treating Hypercholesterolemia? | 13 Dec 2023 | 00:08:08 | |
In this week’s View, Dr. Eagle explores longitudinal changes in pulmonary artery pressure late in life using data from the ARIC study. He then discusses the safety and tolerability of inclisiran for treatment of hypercholesterolemia. Finally, Dr. Eagle asses late gadolinium enhancement in hypertrophic cardiomyopathy and how it improves risk stratification based on current guidelines. | |||
| Eagle’s Eye View: What Are the Key Points to Remember in the 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation? | 06 Dec 2023 | 00:11:17 | |
In this week’s View, Dr. Eagle explores stroke and bleeding risk in patients with atrial fibrillation and a CHA2DS2-VASC risk score of 1. He then discusses the important key points to remember in the recently released 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation. Finally, Dr. Eagle examines the potential value of using high-sensitivity cardiac troponin as a cardiac biomarker to predict preeclampsia.
| |||
| Eagle’s Eye View: What Are the Cardiovascular Effects of Novel Weight Loss Therapies? | 22 Nov 2023 | 00:10:59 | |
In this week’s View, Dr. Eagle explores a meta-analysis of direct oral anticoagulants for stroke prevention in patients with device-detected atrial fibrillation. He then discusses a 20-year study of sudden cardiac death in National Collegiate Athletic Association athletes. Finally, Dr. Eagle examines the cardiovascular effects of novel weight loss therapies. | |||
| Eagle’s Eye View: What is the role of inflammation as a predictor of coronary risk? | 15 Nov 2023 | 00:09:50 | |
In this week’s View, Dr. Eagle explores the role of inflammation as a predictor of coronary risk. He then discusses the safety and efficacy of renal denervation in patients taking antihypertensive medications. Finally, Dr. Eagle examines amiodarone and pulmonary toxicity in atrial fibrillation. | |||
| Eagle’s Eye View: Monday, November 13 — Daily Wrap Up | AHA 2023 | 13 Nov 2023 | 00:12:01 | |
Drs. Kim Eagle, Dharam Kumbhani, Payal Kohli, and Ajay Kirtane review the late-breaking science from the American Heart Association Scientific Sessions 2023 including ESPIRIT (0:34), MINT (3:54), ORFAN (8:25), ARISE and STREAM-2 (11:23). The ACC is providing coverage of the latest science being presented at the AHA Scientific Sessions in Philadelphia. For trial summaries, news coverage, daily video wrap-ups and more, visit ACC's Meeting Coverage Page linked here. Follow the ACC on Social Media and use the hashtag #AHA23. | |||
| Social Determinants of Health in Cardiology, Aortopathy in Children, Cardiac CT Following Left Atrial Appendage Occlusion | 28 Aug 2024 | 00:11:00 | |
In this week’s View, Dr. Eagle looks at the 2024 ACC/AHA key data elements and definitions for social determinants of health in cardiology. He then explores key points of management of aortopathy in children. Finally, Dr. Eagle discusses the recent position statement on the use of cardiac CT following left atrial appendage occlusion. | |||
| Eagle’s Eye View: Sunday, November 12 — Daily Wrap Up | AHA 2023 | 12 Nov 2023 | 00:10:47 | |
Drs. Kim Eagle, Dharam Kumbhani, Payal Kohli, and Ajay Kirtane review the late-breaking clinical trials from day 2, Sunday, November 12 at the American Heart Association Scientific Sessions 2023 including AZAELEA-TIMI 71 (0:38), ARTESIA (5:07) and REPRIEVE (7:52). The ACC is providing coverage of the latest science being presented at the AHA Scientific Sessions in Philadelphia. For trial summaries, news coverage, daily video wrap-ups and more, visit ACC's Meeting Coverage Page linked here. Follow the ACC on Social Media and use the hashtag #AHA23. | |||
| Eagle’s Eye View: Saturday, November 11 — Daily Wrap Up | AHA 2023 | 11 Nov 2023 | 00:11:32 | |
Drs. Kim Eagle, Dharam Kumbhani, Payal Kohli, and Ajay Kirtane review the first day of late-breaking clinical trials at AHA 2023 for Saturday, November 11, including SELECT (0:35), DAPA MI (4:17), and ORBITA2 (7:45). | |||
| Eagle’s Eye View: What is the impact of residual ischemia on cardiovascular mortality in left main bifurcation stenting? | 08 Nov 2023 | 00:09:06 | |
In this week’s View, Dr. Eagle explores the impact of residual ischemia on cardiovascular mortality in left main bifurcation stenting. He then discusses coronary revascularization guided by instantaneous wave free ratio vs. fractional flow reserve and 5-year mortality. Finally, Dr. Eagle examines dyspnea-related ticagrelor discontinuation after percutaneous coronary intervention. | |||
| Eagle’s Eye View: AHA Scientific Sessions 2023 Preview | 03 Nov 2023 | 00:04:07 | |
In this special edition of the View, Dr. Eagle summarizes the top science that will be presented at AHA 2023 from November 11 to November 13 in Philadelphia. Dr. Eagle shares some of the trials that have captured attention, including: SELECT, that investigates semaglutide and cardiovascular outcomes in non-diabetic patients who are overweight or obese; ORBITA-2, a randomized trial that evaluates PCI for Stable Angina; DAPA-MI, a registry-based randomized trial examining the effects of Dapagliflozin in patients with acute myocardial infarction without diabetes; the REPRIEVE study that investigates the effects of pitavastatin on coronary artery disease and inflammatory biomarkers in individuals with HIV; the HEART-1 trial that discusses the safety and pharmacodynamic effects of VERVE-101, an investigational DNA base editing medicine; and the ESPIRIT trial investigating the effects of intensive blood pressure lowering treatment in reducing the risk of cardiovascular events. These trials hold significant promise for advancing the field of cardiology. Our team looks forward to reviewing the results at AHA 2023. There will be daily updates giving more details on these trials and more. | |||